Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics.
An area of unmet medical need in clinical oncology has been optimizing patient selection for a given therapeutic with the goal of getting the right drug to the right patient. Recent studies have developed preclinical approaches to identifying molecular 'signatures of resistance' for cytotoxic therapies and prospective validation of this strategy is ongoing in the clinic. New challenges in this setting include identifying approaches to patient selection for cytostatic compounds such as signaling pathway inhibitors and stem cell targets. Here, we discuss the biomarker methodologies developed using traditional cytotoxic drugs and how these approaches can be adapted to identify biomarkers of patient selection for novel signaling inhibitors and other novel targets. It has become increasingly clear that such biomarker discovery and validation needs to begin early and continue throughout the drug development process.
Sellar
Grant
G
Wyeth Research, Translational Medicine, 500 Arcola Road, Collegeville, PA 19426, USA.
Alvarez
John D
JD
Loganzo
Frank
F
Abbas
Richat
R
Immermann
Fred
F
Karnoub
Maha
M
Feuerstein
Giora Z
GZ
Burczynski
Michael E
ME
Coughlin
Christina M
CM